Immune checkpoints regulate acute myeloid leukemia stem cells. [PDF]
Reinhardt C, Ochsenbein AF.
europepmc +1 more source
Integration of Transcriptome Profiling and Single-Cell Sequencing Analysis to Establish a CD8+ T Cell-Related Prognostic Model for Patients With NSCLC: From Assessment to Therapy. [PDF]
Jiang YY +6 more
europepmc +1 more source
Actionable heterogeneity of hepatocellular carcinoma therapy-induced senescence. [PDF]
Engels P +17 more
europepmc +1 more source
Immune regulatory genes impact the hot/cold tumor microenvironment, affecting cancer treatment and patient outcomes. [PDF]
Sang M +8 more
europepmc +1 more source
c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. [PDF]
Balke-Want H +25 more
europepmc +1 more source
Preliminary screening of urinary host protein biomarkers for Schistosomiasis haematobium: A proteome profiling study identifying candidate diagnostic targets in school-aged children. [PDF]
Liu Y +12 more
europepmc +1 more source
A library of colorectal cancer immunogenic glycopeptides: A step towards novel theragnostics applications [PDF]
Eliana Janine de Paiva Soares
core
Related searches:
CD276 (B7-H3) is an immune checkpoint inhibitor expressed in a majority of solid tumors and hematologic malignancies, however it has not been well-described in acute myeloid leukemia (AML). A variety of immunotherapies targeting CD276 including CAR T cells and antibody-drug conjugates (ADCs) are being explored in solid tumors, however ...
Danielle C Kirkey +11 more
openaire +1 more source
AbstractBackgroundRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood, whose prognosis is still poor especially for metastatic, high-grade, and relapsed RMS. New treatments are urgently needed, especially systemic therapies. Chimeric Antigen Receptor T cells (CAR Ts) are very effective against hematological malignancies, but ...
Andrea Timpanaro +7 more
openaire +1 more source
CD276-positive circulating endothelial cells in advanced colorectal cancer.
Journal of Clinical Oncology, 2019572 Background: The value of circulating endothelial cells (CECs) as predictive biomarker in metastatic colorectal cancer (mCRC) may be improved by using tumor-derived CECs. CD276 can discriminate between tumor derived and normal CECs. We evaluated whether CD276+CEC is a clinically relevant biomarker with 100% sensitivity to predict response to first
Elske C. Gootjes +5 more
openaire +1 more source

